Knight Therapeutics Overview
Valuation check: KHTRF's ROE is 1.84%, below the sector sector average of 11.64%.
Get informed when a big investor buys or sells
+ Follow1.84%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Knight Therapeutics (KHTRF) currently reports a ROE of 1.84%. That is below the sector sector average of 11.64%. Use the charts on this page to explore Knight Therapeutics's ROE history and peer comparisons.
Knight Therapeutics's ROE of 1.84% is lower than the its sector sector average of 11.64%. That is roughly 84.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Knight Therapeutics's current 1.84% should be judged against industry norms (sector average: 11.64%) and against KHTRF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 1.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.64%. From there, open related valuation or income-statement pages for Knight Therapeutics, and consider following KHTRF for alerts when major investors trade the stock.
